Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,023 Mln
P/E Ratio
--
P/B Ratio
1.44
Industry P/E
--
Debt to Equity
0.12
ROE
-0.25 %
ROCE
-22.42 %
Div. Yield
0 %
Book Value
5.92
EPS
-1.52
CFO
$-340.56 Mln
EBITDA
$-508.93 Mln
Net Profit
$-1,184.55 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
10X Genomics Inc (TXG)
| -42.20 | -20.12 | -43.96 | -69.84 | -46.40 | -35.44 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
10X Genomics Inc (TXG)
| -74.05 | 53.57 | -75.54 | 5.20 | 85.70 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.93 | 10,562.04 | 12.43 | 12.69 | |
| 72.80 | 10,050.19 | 97.07 | 2.52 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium... platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. Read more
Co-Founder, CEO & Director
Dr. Serge Saxonov Ph.D.
Co-Founder, CEO & Director
Dr. Serge Saxonov Ph.D.
Headquarters
Pleasanton, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 10X Genomics Inc (TXG) stood at $ 919 Mln as on 31-Dec-24
The share price of 10X Genomics Inc (TXG) is $8.30 (NASDAQ) as of 25-Apr-2025 16:00 EDT. 10X Genomics Inc (TXG) has given a return of -46.4% in the last 3 years.
10X Genomics Inc (TXG) has a market capitalisation of $ 1,023 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of 10X Genomics Inc (TXG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 10X Genomics Inc (TXG) and enter the required number of quantities and click on buy to purchase the shares of 10X Genomics Inc (TXG).
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
The CEO & director of Dr. Serge Saxonov Ph.D.. is 10X Genomics Inc (TXG), and CFO & Sr. VP is Dr. Serge Saxonov Ph.D..
There is no promoter pledging in 10X Genomics Inc (TXG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,078
|
|
|
1,054
|
|
|
964
|
| 10X Genomics Inc (TXG) | Ratios |
|---|---|
|
Return on equity(%)
|
-25.17
|
|
Operating margin(%)
|
-29.09
|
|
Net Margin(%)
|
-29.9
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 10X Genomics Inc (TXG) was $0 Mln.
$-0.01
(
